Short answer
The endocannabinoid system (ECS) is a signaling network. It uses endocannabinoids, enzymes, and receptors. The ECS helps regulate stress, mood, reward, sleep, and pain. Mood disorders include major depressive disorder, anxiety disorders, and bipolar disorder. Research links ECS function to these conditions. The evidence does not prove that cannabis or cannabinoids treat mood disorders. Clinical data are mixed. More human trials are needed.
What the ECS does
The ECS has two main receptors. CB1 receptors sit in the brain and central nervous system. CB2 receptors sit in immune cells and peripheral tissues. The body makes endocannabinoids. Two examples are anandamide and 2-AG. These molecules bind receptors. Then enzymes break them down. FAAH breaks down anandamide. MAGL breaks down 2-AG.
CB1 receptors appear in brain areas that control mood and stress. These areas include the prefrontal cortex, amygdala, hippocampus, and hypothalamus. Animal studies show that ECS signaling changes with stress. Chronic stress can alter endocannabinoid levels. This change may affect mood and behavior.
endocannabinoid system vs cannabinoid receptors
Mood disorders and ECS research
Human studies measure endocannabinoids in blood or cerebrospinal fluid. Some studies find lower anandamide levels in people with depression. Other studies find no link. Results differ by sample, method, and diagnosis. Reviews report mixed findings.
For anxiety, some data show CB1 receptor changes in fear circuits. For bipolar disorder, data are sparse. A 2016 review found few controlled trials. Most studies are small. Many use self-report. Few last longer than 12 weeks.
Cannabis, cannabinoids, and limits
Cannabis contains THC and CBD. THC binds CB1 receptors. CBD does not bind CB1 receptors with high affinity. CBD may affect other targets. Clinical trials of CBD for anxiety show mixed results. Doses range from 300 mg to 600 mg in some studies. Side effects include drowsiness, diarrhea, and liver enzyme changes. THC can raise heart rate and anxiety in some people.
Convenience formats like gummies, vapes, and drinks are common. These formats make use easy. They do not change the clinical evidence.
The FDA has not approved cannabis for depression, anxiety, or bipolar disorder. The FDA has approved CBD for two rare seizure disorders. It has approved THC drugs for nausea and appetite. Those approvals do not cover mood disorders.
Bottom line
The ECS is involved in mood regulation. The link to mood disorders is real but not simple. Current evidence does not support cannabis as a treatment for depression, anxiety, or bipolar disorder. People who take psychiatric drugs should talk with a clinician before using cannabis. Do not stop or change prescribed treatment on your own.